Regenxbio Stock Earnings Reports

REGENXBIO announced positive top-line pivotal results from the Phase III AFFINITY DUCHENNE trial of RGX-2026 (gene therapy for Duchenne muscular dystrophy) and first quarter 2026 financials. Key investor takeaways: 1) Efficacy: The pivotal trial met its primary biomarker endpoint (proportion of patients with microdystrophin >10% at week 12) with 93% (28/30) of patients above that threshold and a mean microdystrophin expression of 71.1% across all patients (41.6% in patients ≥8 years). Interim 12-month functional data (from nine ambulatory patients ≥4 years) show improvements versus external controls across NSAA and timed function tests. A very strong statistical correlation (>0.9) was observed between microdystrophin expression and functional improvement. 2) Safety: RGX-2026 was generally well tolerated in 31 dosed patients with two treatment-related SAEs (one subacute myocarditis and one asymptomatic liver enzyme elevation) that resolved without sequelae. No drug-related thrombocytopenia, myositis, or neurotoxicity reported; liver labs remained stable on average. The program used a proactive short-course immunosuppression regimen (including eculizumab and sirolimus) from the start. 3) Regulatory path and timing: Management is planning for potential accelerated approval in 2027 and intends to engage the FDA to discuss use of microdystrophin as a surrogate endpoint given the strong correlation to function. They acknowledge FDA concern about bias with external controls but believe the magnitude of effect is compelling; options include rolling BLA or full BLA, and the company could adapt confirmatory study design if requested. 4) Development and commercialization outlook: >50 patients have now been dosed across pivotal and confirmatory studies, with a goal of dosing ~60 patients by midyear. Management expects ~50+ patients in the safety database by a potential early-2027 filing and ~15–20 patients with 12-month functional data by that time. Other portfolio notes: retina program (diabetic retinopathy Phase IIb first patient dosing Q2 to trigger $100M milestone from AbbVie), subretinal pivotal data expected Q4, RGX-121 partial clinical hold lifted and CRL appeal filed. 5) Commercial/market considerations: Management emphasized high unmet need, differentiated construct (CT domain microdystrophin), high product purity (high full capsid rate), and physician/family sophistication when evaluating benefit-risk. Overall, data support a potential best-in-class profile with the company preparing regulatory interactions aimed at accelerated approval in 2027.